Navigation Links
SPO Medical Appoints New US Sales Rep Groups

NEW YORK, February 17 /PRNewswire-FirstCall/ -- SPO Medical Inc. (OTC: SPOM - News), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, announced today that it has appointed Med Tech and Med Care Associates as its new independent sales representative group for the US market.

Med Tech and Med Care Associates (MTA/MCA) are independent sales organizations serving the healthcare industry and operate with manufacturers of medical products and devices as their field sales representatives and agents. For SPO Medical MTA/MCA will focus on sales in the US medical professional market and development of the distribution channels for the SPO Medical PulseOx 6000(TM) finger oximeter unit, PulseOx 6100(TM) handheld oximeter unit with interchangeable adult and pediatric sensors and the PulseOx 7500(TM) product line for prescreening of Sleep Apnea.

Michael Braunold, President and Chief Executive Officer of SPO Medical commented: "With increasing challenges in worldwide markets, we sought to extend our reach in the US as our primary market. Through MTA/MCA, we now have an additional 40 experienced and professional sales representatives with expanded coverage throughout the US market. This should vastly extend our distribution capability to medical facilities we could not reach before and strengthen our overall presence and penetration in the territory."

Dennis Snedden, President of MTA commented: "We are pleased to add SPO Medical as one of the manufacturers our team represents. SPO's reputation for their products and customer service is a perfect match for the commitment and support that MTA/MCA is renowned for, with its customer base of leading distributors to the professional medical markets."

Jack Moran, President of MCA commented: "Our sales representatives are all primed for the task at hand and look forward to achieving together with SPO Medical growth for all their professional market product lines in the US."

Michael Braunold added: "We have built our relationship with MTA/MCA over a number of months and are confident that they will bring the value-added to our sales efforts in the US market. We look forward to working with this team of professionals."

About SPO Medical:

SPO Medical (SPOM) a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices to capture life-saving and life-enhancing information within four key markets: medical care; home and remote-care; sports and wellness; and safety and security. Its patented technology uses information gathered from the reflectance of light on the human blood stream, in a non-invasive manner, to monitor key vital signs. The Company distributes its products through a network of distributors and also licenses its technologies to appropriate client corporations for commercialization and distribution. For more information, visit and

About MedTech Associates

MTA/MCA was formed twenty-five years ago to address the growing need to offer professional sales representation for both established and emerging health products companies.

Forward Looking Statements:

This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry, and that reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to, market acceptance of our products, changes in economic conditions generally and the medical devices market specifically, changes in technology, legislative or regulatory changes that affect us, the availability of working capital, the introduction of competing products, changes in our operating strategy or development plans and the risks and uncertainties discussed under the heading "Risk Factors" in Item 1 of our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007. We undertake no obligation to revise or update any forward-looking statement for any reason.

    Investor Contacts:

    SPO Medical Contact:             Michael Braunold,
                                     President and CEO
                                     +1-866-991-SPOM (7766)

    Medtech Associates Contact:      Julee Prefer,
                                     VP Marketing and Distributor Relations

SOURCE SPO Medical Inc
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Avantis Medical Systems Announces FDA 510(k) Clearance for the Third Eye(R) Retroscope(R) for Improved Polyp Detection in the Colon
2. Hong Kong Biotech Company, Filligent, Announces CE Certification of Its Revolutionary, Anti-Infective Medical Face Mask, the BioMask
3. American Institute for Medical and Biological Engineering Appoints Dr. Gualberto Ruano to College of Fellows
4. Cordex Pharma Forms Heart Failure Medical Advisory Board
5. Former SADMERC Medical Directors Join OrthoCare Innovations as Medical and Scientific Advisory Board Members and Strategic Advisors
6. The Holtorf Medical Group and Yan Center for Corrective & Cosmetic Surgery Tap 5W Public Relations
7. Informed Medical Communications Appoints New Vice President, Information Technology
8. Aerovance Appoints Babatunde A. Otulana, M.D., as Chief Medical Officer
9. China Sky One Medical, Inc. CFO to Present at Roth Conference
10. BioMS Medical to present at BIO CEO and Investor Conference
11. Texcel Highlights Medical Device Development & Manufacturing Solutions at MD&M West, booth 314
Post Your Comments:
(Date:6/27/2016)... June 27, 2016  Sequenom, Inc. (NASDAQ: ... healthier lives through the development of innovative products and ... the United States denied its petition ... claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") ... established by the Supreme Court,s Mayo Collaborative Services v. ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf ... join the faculty of the University of North Carolina Kenan-Flagler Business School ... and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of the ... brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing ... to its list of well-respected retailers. This list includes such fine stores as ...
Breaking Biology Technology:
(Date:5/12/2016)... May 12, 2016 , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
Breaking Biology News(10 mins):